The KEYNOTE–010 trial only enrolled patients with PD–L1 expressed NSCLC, and found that patients with a tumor proportion score (TPS) for PD–L1 of at least 50% achieved a superior outcome (34). The gene discussed is CD274; the disease is neoplasm.